Back to results
US 9,845,357 B2Granted
Integrin αvβ8 neutralizing antibody
AssigneeThe Regents of the University of California
InventorsStephen Nishimura, Jianlong Lou, Jody Lynn Baron, James D. Marks
Life of this patent
Estimating the term…
Abstract
The present invention relates to αvβ8 antagonists, anti-αvβ8 antibodies or immunoconjugates for reducing TGFβ activation in an individual. Further provided are compositions comprising one of the αvβ8 antagonists, anti-αvβ8 antibodies or immunoconjugates, methods for using the compositions, and related subject matter.
Claims11
A method of reducing TGFβ activation in an individual, the method comprising administering an antibody that specifically binds αvβ8, wherein the antibody comprises a heavy chain variable region that comprises a CDR1 sequence of SEQ ID NO:
- 5, a CDR2 sequence of SEQ ID NO:
- 6, and a CDR3 sequence of SEQ ID NO:
- 7, and a light chain variable region that comprises a CDR1 sequence of SEQ ID NO:
- 8, a CDR2 sequence of SEQ ID NO:
- 9, wherein Xaa in SEQ ID NO:9 is tyrosine, and a CDR3 sequence of SEQ ID NO:
- 10, thereby reducing TGFβ activation in the individual.
3 more elements
Dependencies are inferred from the claim text.